Filing Flows

Filing Flows › Edwards Lifesciences (EW) › Next earnings date

Edwards Lifesciences (EW) earnings: beat the estimate

Edwards Lifesciences (EW) reported on Nov 4, 2026 and beat the EPS estimate: $0.80 against $0.74 (+8.6%). Revenue was $1.7B for Q3 2026, +10% year over year. It beat the EPS estimate in 80% of the quarters on record.

Last result+8.6% vs estimate
Beat rate80%

The last report

Edwards Lifesciences reported revenue of $1.7B for the third quarter 2026 (+10% Y/Y), net earnings $308M: Transcatheter Aortic Valve Replacement $1.2B, Surgical $264M, Transcatheter Mitral and Tricuspid Therapies $210M. How it makes money → · Every quarter →

Edwards Lifesciences: EPS against the estimate, last 5 reportsEdwards Lifesciences: EPS against the estimate, last 5 reportsEstimateReported$0.59$0.67Oct 25$0.62$0.58Feb 26$0.73$0.78Apr 26$0.74$0.78Jul 26$0.74$0.80Nov 26
Latest (Nov 26): Estimate $0.74, Reported $0.80.
EW: the stock's move on each reportEW: the stock's move on each reportJul 23, 2026-2.1%Apr 23, 2026+3.2%Feb 10, 2026+3.3%Oct 30, 2025-0.3%

Edwards Lifesciences' latest quarter

Edwards Lifesciences, Q3 2026: revenue $1.7B (+10% year over year), operating margin 17.4%, net earnings $308M, operating cash flow $570M. The chart follows the revenue to costs, profit and cash.

Questions

Did Edwards Lifesciences beat earnings?

Edwards Lifesciences (EW) reported on Nov 4, 2026 and beat the EPS estimate: $0.80 against $0.74 (+8.6%).

When does EW report earnings?

The next date is not set yet.

Does Edwards Lifesciences usually beat earnings?

It beat the consensus EPS estimate in 80% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.